Methylphenidate-Induced Stuttering in a Patient With Autism Spectrum Disorder and Attention Deficit Hyperactivity...

Area of Science:

• Neurodevelopmental disorders
• Pediatric psychiatry
• Pharmacology

Background:

• Autism spectrum disorder (ASD) is characterized by social communication deficits and repetitive behaviors.
• Attention deficit hyperactivity disorder (ADHD) frequently co-occurs with ASD, necessitating tailored treatment plans.
• Methylphenidate (MPH) is a first-line ADHD treatment, but potential adverse effects in children with ASD require consideration.

Purpose of the Study:

• To present a case of a child with ASD and ADHD who developed stuttering upon initiation of MPH treatment.
• To discuss the literature regarding the relationship between MPH and stuttering in this population.

Main Methods:

• A 10.5-year-old boy diagnosed with ASD and ADHD was treated with OROS MPH.
• The dosage was increased, and the onset of stuttering was observed.
• MPH was discontinued, and the effect on speech fluency was monitored.
• MPH was later reintroduced to confirm the association.

Main Results:

• ADHD symptoms improved moderately with MPH treatment.
• Stuttering emerged one week after increasing MPH dosage and resolved upon discontinuation.
• Reintroduction of MPH at the same dosage led to the recurrence of stuttering.
• The patient's treatment was switched to atomoxetine.

Conclusions:

• The relationship between MPH and stuttering is not extensively documented.
• Adverse effects like stuttering can occur with MPH initiation or dosage increase.
• Discontinuation of MPH typically resolves such side effects.
• Further research is needed to understand MPH's side effects and mechanisms in co-occurring ASD and ADHD.